Back to Search
Start Over
P261 Local and systemic relaxin-2 expression is modulated in patients undergoing heart transplantation.
- Source :
- Cardiovascular Research; Jul2014, Vol. 103 Issue suppl_1, pS47-S47, 1p
- Publication Year :
- 2014
-
Abstract
- Human Relaxin-2 is best known for its physiological role during pregnancy in the growth and differentiation of the reproductive tract as well as in the renal and systemic hemodynamic changes. This factor can also be involved in the pathophysiology of arterial hypertension and heart failure. Within the last years, Relaxin-2 is already being considered as a promising drug, especially in acute heart failure. RLX030, a recombinant form of Relaxin-2 has shown promising results in the therapy of acute heart failure. However, the role of Relaxin-2 in chronic heart failure has not been detailed investigated yet.We examined the systemic and local expression of Relaxin-2 in patients suffering from chronic heart failure (CHF) undergoing heart transplantation or LVAD implantation (CHF; n=7). Myocardial tissue samples and blood samples of the patients were collected after ethic approval and analyzed via immunohistochemical staining and ELISA analysis, respectively. Homografts and blood samples from by-pass surgery patients with EF>65% served as control group (Control; n=5). Data are expressed as mean±SEM. The statistical differences were determined by unpaired Student t-test and One-Way Anova, as appropriate, using GraphPad Prism 6 software. p<0.05 was considered as statistically significant.The immunohistochemical staining for Relaxin-2 showed a significant higher protein expression in the CHF group compared to the controls (Control 26.49±1.37% vs. CHF 31.35±0.61%; p<0.05). The evaluation of the circulating levels of Relaxin-2 did not show significant differences. However, a trend in elevated Relaxin-2 levels in the CHF group compared to controls was observed (Control 15.32±0.11pg/ml vs. CHF 19.41±3.78pg/ml).Relaxin-2 has been successfully evaluated as a new drug for the treatment of patients with acute heart failure. Our data provide evidence about the promising role of Relaxin-2 in CHF. We have found an up-regulated tissue expression of this protein. Thus, Relaxin-2 seems to provide therapeutic potential of being a novel drug for CHF. [ABSTRACT FROM PUBLISHER]
Details
- Language :
- English
- ISSN :
- 00086363
- Volume :
- 103
- Issue :
- suppl_1
- Database :
- Complementary Index
- Journal :
- Cardiovascular Research
- Publication Type :
- Academic Journal
- Accession number :
- 96949537
- Full Text :
- https://doi.org/10.1093/cvr/cvu082.192